CLINICAL TRIALS PROFILE FOR NIRAVAM
✉ Email this page to a colleague
All Clinical Trials for NIRAVAM
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00266409 ↗ | Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder | Completed | UCB Pharma | Phase 4 | 2005-10-01 | An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to that in subjects treated with a newly prescribed SSRI/SNRI alone. Subjects must be at least 18 years of age and positive for Generalized Anxiety Disorder (GAD)or Panic Disorder. Subjects will be randomized to receive concomitant Niravam™ and an SSRI/SNRI or an SSRI/SNRI alone during the study. Most symptom evaluations will be done using an automated phone interview system. There are 4 clinic visits. |
NCT01188031 ↗ | A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions | Completed | Actavis Inc. | Phase 1 | 2006-06-01 | This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2 mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs Inc.®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult volunteers administered under fasting conditions. |
NCT01188057 ↗ | A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions | Completed | Actavis Inc. | Phase 1 | 2006-07-01 | This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2 mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs Inc.®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult volunteers administered under non-fasting conditions. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NIRAVAM
Condition Name
Clinical Trial Locations for NIRAVAM
Trials by Country
Clinical Trial Progress for NIRAVAM
Clinical Trial Phase
Clinical Trial Sponsors for NIRAVAM
Sponsor Name